Iridex to Report First Quarter 2024 Financial Results on May 14, 2024
Iridex (NASDAQ: IRIX) will report its financial results for the first quarter of 2024 on May 14, 2024. The company specializes in laser-based medical systems for glaucoma and retinal diseases, with a conference call scheduled after the market closes.
- None.
- None.
MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter 2024 after the close of trading on Tuesday, May 14, 2024.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at: www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
When will Iridex report its financial results for the first quarter of 2024?
What is the specialty of Iridex ?